Latest KFF Health News Stories
Inside the Tactical Tug of War Over the Controversial Alzheimer’s Drug
An epic battle is playing out behind the scenes over whether the government should pay for Aduhelm, an FDA-approved Alzheimer’s drug that scientists say has not been proven to work.
Don’t Nurse That Moscow Mule — It Could Be a Health Hazard
Researchers in Montana have found that unsafe levels of copper can leach into the cocktail in less than half an hour.
Cuidado con este cóctel, puede ser peligroso para la salud
El Moscow Mule se toma en una jarra de cobre, lo que lo vuelve fascinante, y tal vez peligroso.
KHN’s ‘What the Health?’: FDA Takes Center Stage
Congress is set to start its once-every-five-years review of the law that authorizes user fees to finance the hiring of personnel to speed the FDA review of drugs. The periodic renewals of “PDUFA” also give lawmakers a chance to make other changes to the agency at the hub of the pandemic. Meanwhile, the FDA could also find itself at the center of the abortion debate and a controversial new medication to treat Alzheimer’s disease. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Paging the HHS Secretary
Health and Human Services Secretary Xavier Becerra is drawing criticism for his hands-off handling of the covid crisis even though the heads of the Centers for Disease Control and Prevention, National Institutes of Health, and FDA report to him. Meanwhile, the Department of Labor looks to enforce mental health “parity laws” that have failed to achieve their goals. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN’s Noam N. Levey, who reported and wrote the latest KHN-NPR “Bill of the Month” episode about a large emergency room bill for a small amount of medical care.
KHN’s ‘What the Health?’: Dealing With Drug Prices
Medicare officials tentatively plan to restrict the use of a controversial Alzheimer’s drug to only those patients participating in clinical trials, while the Department of Health and Human Services looks into lowering the monthly Medicare Part B premium. Meanwhile, covid confusion still reigns, as the Biden administration moves, belatedly, to make more masks and tests available. Joanne Kenen of Politico and the Johns Hopkins Bloomberg School of Public Health, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
‘An Arm and a Leg’: The Rapid-Test Edition: Who’s Making a Buck?
In this episode, host Dan Weissmann talks to reporters who investigated the shortage of tests and traced the U.S. rapid-testing problem back to government agencies.
The Vaccine Rollout Was a Success. But Events Within and Beyond Biden’s Control Stymied Progress.
There were variants, vaccine hesitancy and messaging mix-ups. And, despite campaign promises, Biden and his administration sometimes took actions or made statements without waiting for full scientific evidence to back them up.
KHN’s ‘What the Health?’: Oh, Oh, Omicron
Even before the omicron variant of covid starts to spread widely in the U.S., hospitals are filling up with post-holiday delta cases. Meanwhile, the Supreme Court signals — loudly — that 2022 will be the year it rolls back abortion rights in a big way. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.
Con más muertes por sobredosis, defensores claman por una naloxona de venta libre
La administración Biden ha destinado $30 millones a programas de reducción de daños por adicciones. Pero defensores dicen que la principal barrera es que la naloxona sigue siendo de venta bajo receta.
With Overdose Deaths Surging, Advocates on the Ground Push for Over-the-Counter Naloxone
Harm-reduction groups say that requiring a doctor to sign off on their orders of the overdose reversal drug is one of the biggest barriers they face in obtaining the lifesaving medication.
¿Ha llegado el momento de cambiar la definición de “totalmente vacunado”?
Científicos y funcionarios de salud pública debaten cuándo será el momento de cambiar la definición de “totalmente vacunado” para que incluya una vacuna de refuerzo.
Is It Time to Change the Definition of ‘Fully Vaccinated’?
Experts weigh in as the federal government urges everyone to get boosted amid concerns over omicron, a new covid variant.
Hospitals Refused to Give Patients Ivermectin. Lockdowns and Political Pressure Followed.
Hospitals in Montana and Idaho reported threats and harassment from public officials and family members of patients who were denied treatment with a drug not authorized to treat covid-19.
KHN’s ‘What the Health?’: The Big Biden Budget Bill Passes the House
President Joe Biden’s social spending budget is on its way to the U.S. Senate, where Democratic leaders are (optimistically) hoping to complete work by the end of the year. Meanwhile, covid is surging again in parts of the country, along with the political divides it continues to cause. Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and the Johns Hopkins School of Public Health, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner previews next week’s Supreme Court abortion oral arguments with Florida State University law professor Mary Ziegler.
Why You Can’t Find Cheap At-Home Covid Tests
You probably won’t be testing everyone at your Thanksgiving table for covid because the tests are expensive and hard to find. Why? The federal government is partly to blame.
KHN’s ‘What the Health?’: Boosting Confusion
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer’s disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the “An Arm and a Leg” podcast.
KHN’s ‘What the Health?’: Biden Social-Spending ‘Framework’ Pulls Back on Key Health Pledges
President Joe Biden unveiled a compromise “Build Back Better” framework shortly before taking off for key meetings in Europe, but it’s unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the party’s health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHN’s Julie Rovner to discuss these issues and more.
KHN’s ‘What the Health?’: Dems Agree to Agree, But Not on What to Agree On
Negotiations on the health parts of President Joe Biden’s domestic agenda are getting serious but have yet to produce a deal every Democrat can support. Meanwhile, the Food and Drug Administration remains without a nominated leader but manages to take the first steps toward approving over-the-counter hearing aids. Joanne Kenen of Politico and Johns Hopkins, Tami Luhby of CNN and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read too.
Watch: Going Beyond the Script of ‘Dopesick’ and America’s Real-Life Opioid Crisis
KHN teamed up with Hulu for a discussion of America’s opioid crisis, following the Oct. 13 premiere of the online streaming service’s new series “Dopesick.”
